Preclinical Validation Hub
One of the Oxford Centre’s key aims is to develop scientific advances made in cancer research at Oxford University, into patient benefit. The Preclinical Validation Hub is a facility available to all Oxford based researchers to support the development of their discoveries, to the point of clinical testing.
Find out more about the Preclinical Validation Hub from the team, below.
Oxford has considerable breadth and depth of expertise in fundamental cancer research. While in some areas (e.g. anti-angiogenesis), basic science has been effectively translated into significant patient benefit, in other areas (e.g. radiobiology, aspects of cell signalling) there have been insufficient tools available to develop discoveries made by researchers at the University, to the point of clinical testing. Recognising this, the Centre has established a Pre-clinical Validation Hub to support research in two key areas:
The aim of our team is to support translational research with the ultimate goal to improve the design, quality and potential impact of our in-house clinical trials. We are available to all members of the CRUK Oxford Centre and are very happy to talk about your research and how the Preclinical Validation Hub may be able to help. Use the contact form at the bottom of the page to get in touch.
Dr Valentine Macaulay
We use robust and well-validated assays based on existing protocols and expertise within the Cancer Research UK Oxford Centre. The data quality is at a level that is suitable for publication and if appropriate, patenting. All cell lines are authenticated before use. See below for some of the key in vitro assays and in vivo studies that we can offer or use the contact form on this page if you have a method not listed but you’d like to discuss with us.
Use the contact form below if you have a more general question about how the Preclinical Validation Hub works, and how you can access this resource. If you are ready to make a project application to the team then the Research Proposal form is below.